Elecsys®抗苗勒管激素检测预测卵巢对corifollitropin alfa反应的价值
这项多中心前瞻性研究纳入219例接受150 μg corifollitropin alfa治疗的女性,评估Elecsys® AMH检测预测卵巢反应的能力。AMH预测低反应的AUC为0.883,预测高反应的AUC为0.865;AMH与窦卵泡计数是CFA治疗患者卵巢反应的最佳预测指标。
要点
- Elecsys® AMH可预测CFA拮抗剂方案下的卵巢反应。
- AMH预测低卵巢反应AUC为0.883,优于AFC的0.879。
- AMH预测高卵巢反应AUC为0.865,优于AFC的0.822。
核心结论
- 自动化Elecsys® AMH检测可预测CFA拮抗剂方案中的卵巢反应。
- AMH和AFC是CFA治疗患者卵巢反应的最佳预测指标。
研究设计与样本
- 纳入18-43岁、月经规律、BMI 17-35 kg/m2且体重≥60 kg的女性,共219例。
- 所有患者接受150 μg CFA后行固定GnRH拮抗剂方案,联合重组FSH 150-300 IU/天。
主要发现
- 219例中低卵巢反应(卵母细胞≤3个)占22.8%,正常反应占66.2%,高卵巢反应(卵母细胞≥15个)占11%。
- 预测低卵巢反应:AMH的AUC为0.883(95%CI 0.830-0.936),AFC的AUC为0.879(95%CI 0.826-0.930)。
- 预测高卵巢反应:AMH的AUC为0.865(95%CI 0.793-0.935),AFC的AUC为0.822(95%CI 0.734-0.909)。
关键数值与推荐
- AMH截断值1.0 ng/ml预测低卵巢反应,灵敏度92.0%,特异度66.9%。
- AMH截断值2.25 ng/ml预测高卵巢反应,灵敏度54.2%,特异度91.8%。
临床怎么用
- 可用Elecsys® AMH检测联合AFC评估CFA方案前的卵巢反应风险。
- AMH 1.0 ng/ml以下提示低反应风险高,2.25 ng/ml以上提示高反应风险高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What is the performance of anti-Müllerian hormone (AMH) as measured by the Elecsys® AMH assay in predicting ovarian response in women treated with 150 µg corifollitropin alfa (CFA)? DESIGN: Multicentre, prospective study conducted between December 2015 and April 2018. Women were aged 18-43 years, had regular menstrual bleeding, a body mass index of 17-35 kg/m2 and weighed 60 kg or over. EXCLUSION CRITERIA: previous oophorectomy, history of ovarian hyperstimulation syndrome, a previous IVF and intracytoplasmic sperm injection cycle producing over 30 follicles measuring 11 mm or wider, basal antral follicle count (AFC) over 20 or polycystic ovarian syndrome. All women were treated with 150 μg CFA followed by recombinant FSH (150-300 IU/day) in a fixed gonadotrophin releasing hormone antagonist protocol. RESULTS: Of the 219 patients enrolled, 22.8% had low ovarian response (three or fewer oocytes), 66.2% had normal response and 11% had high ovarian response (15 or more oocytes). The AMH and AFC presented an area under the curve of 0.883 (95% CI 0.830 to 0.936) and 0.879 (95% CI 0.826 to 0.930), respectively, for low ovarian response; and an AUC of 0.865 (95% CI 0.793 to 0.935) and 0.822 (95% CI 0.734 to 0.909) for high ovarian response. An AMH cut-off of 1.0 ng/ml provided a sensitivity of 92.0% and a specificity of 66.9% in the prediction of low ovarian response; a cut-off of 2.25 ng/ml predicted high ovarian response with a sensitivity of 54.2% and a specificity of 91.8%. CONCLUSIONS: The automated Elecsys® AMH assay predicts ovarian response in a CFA antagonist protocol. The best predictors of ovarian response in CFA-treated patients were AMH and AFC.
引用
- Neves AR, Blockeel C, Griesinger G, et al. The performance of the Elecsys® anti-Müllerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa. Reprod Biomed Online. 2020. PMID: 32466992. doi:10.1016/j.rbmo.2020.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。